objective To evaluate the quality of omeprazole personally imported into Japan via the Internet and to compare the quality of these samples with previously collected samples from two other Asian countries.
Introduction
One of the major challenges to global health is the growing burden of non-communicable diseases (NCDs), which are predicted by the World Health Organization (WHO) to be the leading cause of death and disabilities worldwide by 2030 [1, 2] . Among the NCDs, gastroesophageal reflux disease (GERD) is one of the most common [3] . It is often treated with a proton pump inhibitor, such as omeprazole, which is available as an over-the-counter (OTC) drug in many countries, but is a prescription drug in Japan [4] . However, the recent rise in e-commerce and the proliferation of illicit online pharmacies has enabled patients in Japan to obtain many drugs directly, with or without a prescription [5, 6] . Indeed, LegitScript's annual report in 2016 estimated that about 3,000 websites, or 10% of the world's rogue Internet pharmacies, take Japan as their primary target, making it the second largest market for illegal online drug sellers [7] . This is an important issue because of the potential for proliferation of substandard and falsified medicines.
Substandard medicines may be prepared by legitimate manufacturers, who fail to meet pharmacopoeial standards due to accidental breaches of good manufacturing practice, or may be a consequence of inadequate storage conditions in the distribution chain [8, 9] . On the other hand, falsified medicines are produced and sold with deliberate misrepresentation of their origin, authenticity or effectiveness. These products circulate because of the constant demand for medicines and weaknesses in national regulatory systems [10] . The term falsified medicine is often broadly used to cover substandard, spurious, falsely labelled, falsified and counterfeit (SSFFC) medicinal products.
According to PSI (Pharmaceutical Security Institute) data, the prevalence of falsified medicines has increased drastically between 2002 and 2012 [11] . Even so, the reported prevalence would likely have been higher if resource-poor countries had adequate follow-up and reporting systems [12] . Also, drug-regulatory authorities in countries with adequate law enforcement and pharmaceutical companies conducting oversight do not necessarily release their records publicly [10, 12, 13] . The seriousness of the situation is illustrated by the fact that in 2010, about 67% of omeprazole samples collected from Cambodia proved unacceptable in quality tests (about 98% of these samples had been imported from various countries) [14] . Also, about 50% of omeprazole samples from Myanmar proved unacceptable in quality tests in 2014 (100% of them were imported) [15] .
In this context, the present investigation was undertaken with the primary objective of evaluating the quality of omeprazole ordered via the Internet and personally imported into Japan. We also examined whether there was a quality difference between these personally imported products and products previously collected in other Asian countries and labelled as being manufactured by the same companies.
Methods

Source selection and collection of samples
The Google Japan search engine was used to search for pharmacies offering omeprazole product. The searches were performed during the 19th August to 12th September 2013. The search terms used were 'オメプラゾール and 個人輸入' for Japanese sites and 'Omeprazole and personal import' for English sites. Among the hits, pharmacies offering omeprazole 20 mg tablets or capsules were selected. Samples purchased from the Internet sites of organisations located outside Japan were personally imported into Japan during August to September 2013.
Observation test
Each sample was assigned a code upon receipt. Details of the packaging condition, label information, product name, dosage form, dosage strength, manufacturers' name and address, batch number, manufacturing and expiry dates were noted and evaluated according to the FIP (International Pharmaceutical Federation) checklist [16] .
Authenticity investigation
The methodology of the authenticity investigation and registration verification was adopted from WHO [17] [18] [19] . A questionnaire accompanied by a photograph of the sample was sent to the relevant manufacturing company for confirmation of authenticity. Printed information from the product package was also verified from the manufacturers' website. The regulatory authorities in the countries of origin and distribution were also contacted to verify the legitimacy of the products and their approval for marketing.
Quality analysis
Materials. Reference standard omeprazole was procured from USP Pharmacopeial Convention, and omeprazole standard capsules were a gift from AstraZeneca. Lansoprazole as an internal standard was purchased from Sigma-Aldrich (India). NaH 2 PO 4 .2H 2 O, Na 2 HPO 4 , Na 3 PO 4 , KH 2 PO 4 and other chemicals of reagent grade were purchased from Nacalai Tesque Inc. (Kyoto, Japan). Distilled water was used for the preparation of HPLC eluents.
Analytical procedure. Among the total of 28 samples collected, six were tablets and 22 were capsules. For the identification test to verify the identity of the active pharmaceutical ingredient (API), the chromatogram of the sample was compared with that of the reference standard omeprazole. Quantity (to determine whether the labelled amount of the API in the sample is correct), content uniformity (to examine the consistency of dosage units, each unit in a batch should have a drug substance content within a narrow range around the label claim) and dissolution test (to determine compliance with the pharmacopoeial in vitro drug release requirements) were carried out according to the pharmacopoeia indicated in the package insert or on the outer package of each sample [20] [21] [22] [23] [24] [25] . A high-performance liquid chromatography (SPD-20A/20AV Series; Shimadzu, Kyoto, Japan) with a photodiode array detector was used.
The dissolution test was performed with an NTR-VS 6P dissolution apparatus (Toyama Sangyo Co. Ltd., Osaka, Japan). Drug release studies were carried out by the paddle apparatus (USP dissolution apparatus 2). The paddle was set to rotate at 100 rpm and the temperature was maintained at 37 AE 0.5°C.
Standard solutions were prepared by dissolving accurately weighed quantities of omeprazole (reference standard) and lansoprazole (internal standard) in the diluent to obtain solutions with concentrations of 0.2 mg/ml and 0.1 mg/ml, respectively. From these stock solutions, five diluted omeprazole solutions (0.2, 0.15, 0.1, 0.05 and 0.025 mg/ml) were prepared. The relationship between the peak area and concentration was linear within the range of 0.025-0.2 mg/ml of the active ingredient (r 2 = 0.999-1.000), and the quality test was performed within that range. Acceptance criteria of the sample were set according to the respective pharmacopoeia requirements.
Quality difference among products from the same manufacturers in different market segments
In Cambodia 2010, a study conducted by Yoshida et al. [14] found serious quality deficiencies, especially in the dissolution test, in omeprazole samples from some manufacturers. Similar results were reported from Myanmar in 2014 by Rahman et al. [15] . Interestingly, manufacturers of those poor-quality products had also produced some of the samples obtained in our current study. The samples from Cambodia and Myanmar had mainly failed the dissolution test in the acid stage, indicating ineffective enteric coating to protect omeprazole in the core.
Raman spectroscopy was applied to analyse the molecular structure by light scattering. The purpose of the test was to compare six representative products from two of the same manufacturers, collected at different sites. The test was performed using an Inspector 500 (SciAps Inc., USA) equipped with higher wavelength Raman excitation, consisting of a 300 mW 1030 nm Class III B laser and a cooled Type III-IV semiconductor detector array (spectral range 100-2500 cm
À1
). The concordance rate was calculated using the NuSpec Pro software (SciAps Inc., USA). Granules of each sample were placed in front of the laser source (three times each for three different granules), and the Raman spectral data were recorded and compared with those of the standard sample.
Data analysis
Data analysis was performed using Microsoft Excel 2010, and Principal component analysis (PCA) of Raman spectra was analysed using the Unscrambler (Camo Software, Oslo, Norway). The PCA was employed to approximate the observed Raman spectra in terms of two major components. The purpose of PCA was to examine whether there were differences between the Raman data obtained from the compared samples. PCA was performed on smoothed spectra to determine potential grouping for subsequent classification.
Results
Internet pharmacy sites
A total of 31 sites selling omeprazole were found. Among them, 13 sites were in Japanese and the other 18 sites were in English. Among the 13 Japanese-language sites, none asked for a prescription, and 26 samples of 16 different products were purchased from these sites. Among the 18 English sites, 16 asked for a prescription (which was obviously not available for this study) and the other two sold omeprazole as an OTC product. Two additional samples of the same product were purchased from these two sites. Among the 31 sites, two did not give any physical address, two sites had no contact phone number and six sites did not recommend consultation with a physician or pharmacist.
Sample observation
We purchased 28 samples, which were labelled as being from 17 different manufacturers in six countries, and were distributed from 7 different countries. Examination according to the FIP checklist revealed that one sample had no manufacturer's name or batch number. One sample was different from the ordered sample advertised on the site. One sample was found with loose granules outside the capsule shell, and one sample was found with a cracked capsule shell.
Authenticity investigation
A questionnaire was sent to each manufacturer for product authenticity and legality investigation, as well as to the manufacturing country and country of distribution. None of the 17 manufacturers responded. In a legality investigation, two manufacturing countries among six replied that eight samples were legal. Among the seven distribution countries (11 distributors), replies were received from three countries, and one distributor was found to be licensed.
Quality test result
In the identification test, the retention time of the principal peak in all the sample chromatograms was similar to that of the peak of standard omeprazole, and the UV spectra of the standard and samples were identical. The results of the quality tests are summarised in Table 1 .
Raman spectroscopic analysis
In the case of manufacturer X, the similarity of the Myanmar product to the personal import product was 62%, and that of the Cambodian product to the personal import was 68%; in contrast, the similarity of the Cambodian and Myanmar products was 94% ( Figure 1a-c) . In the case of manufacturer Y, the similarity of the Myanmar product to the personal import product was 94%, and that of the Cambodian product to the personal import was 92%, whereas the similarity of the Cambodian and Myanmar products was 98% (Figure 2a-c) . To ensure the observed differences, Raman spectra of the respective samples from manufacturer X & Y were further evaluated by PCA. The PCA results obtained with Raman spectra demonstrated the similar variation to clearly distinguish the samples from the same manufacturers (data not shown).
Discussion
The omeprazole samples purchased through the Internet and imported into Japan for personal use have mostly passed the quantity and content uniformity tests, and all the samples passed the identification and dissolution tests. However, many of the sites were selling omeprazole without prescription, although omeprazole is a prescription medicine in Japan. Some sites did not provide a physical address or contact number. Most importantly, one did not deliver the advertised product to the consumer. Illicit online pharmacies do not necessarily provide detailed information about proper use of their products [26, 27] . As has previously been noted, there was no response to our inquiries about product authenticity and legality [18, 28] . Thus, there is a clear risk to consumers who purchase products via the Internet, even if the quality of most products is adequate, as in this study.
Another aim of this study was to assess whether there was a quality difference between the same products from the same manufacturer distributed in different countries. Indeed, we found that the quality of the products imported personally through the Internet in Japan was much better than that of corresponding samples previously collected in Cambodia and Myanmar. In particular, omeprazole samples from two manufacturers, collected in Cambodia and Myanmar, failed dissolution tests, whereas the corresponding products delivered to Japan passed. For manufacturer X, the Raman-based difference in correspondence between personal import omeprazole and Cambodian or Myanmar omeprazole was 30-40%. There was also a difference in the case of manufacturer Y, although it seemed smaller from Raman data but the PCA analysis demonstrated a clearly distinguishable variation of the samples. Although small variations in purity, size, strength and other parameters are permitted, a difference of nearly 40% is unlikely to be compatible with good manufacturing practice (GMP) [29] . It has been reported that some manufacturers intentionally produce substandard medicines to exploit regulatory loopholes for commercial gain [10, 30] . In general, non-adherence to GMP and GDP as well as high demand for medicines underpins the circulation of these poor-quality medicines. Possible reasons include unreliable supply of medicines in the face of high demand, or lack of infrastructure of medicine regulatory authorities (MRAs) to assess whether imported medicines are of the required quality, safety and efficacy. We cannot rule out such possibilities in the present case, although it should be borne in mind that other factors, such as improper storage conditions in the distribution chain, might have contributed to the properties of the medicines.
A limitation of our study was that we evaluated only one drug in this study. Another limitation was the relatively small number of samples and Internet sites from which they were collected. Nevertheless, we were able to identify suspicious sites and suspicious samples. Despite the aforementioned limitations, the low response rate in authenticity investigation was of concern, highlighting the need for better cooperation from manufacturers and regulatory authorities.
Conclusions
Omeprazole formulations are readily available online with or without a prescription. The quality of omeprazole samples purchased via the Internet and personally imported into Japan was mostly satisfactory. Nevertheless, the same products from some of the same manufacturers, previously collected in surveys in Cambodia and Myanmar, had proved unsatisfactory, especially as regards dissolution properties [14, 15] . Further investigation is needed to establish whether some manufacturers are intentionally producing substandard medicines for sale in certain market segments or whether other factors are involved.
